Lung Transplant Rejection – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Lung Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions.
Lung transplantation is the therapy used in various lung diseases. A lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously that prevent the body from either identifying or attacking the foreign organ via various immune responses, thus blocking organ rejection and facilitating a successful transplant.
The Lung Transplant Rejection drugs in development market research report provide comprehensive information on the therapeutics under development for Lung Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Lung Transplant Rejection | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Lung Transplant Rejection therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Lung Transplant Rejection pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Lung Transplant Rejection treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Amniotics ABApeptico Research and Development Ltd
Bristol-Myers Squibb Co
Cell2Cure Aps
Isopogen Pty Ltd
Kadmon Holdings Inc
MimeTech Srl
Radikal Therapeutics Inc
Renovion Inc
Takeda Pharmaceutical Co Ltd
TFF Pharmaceuticals Inc
Trove Therapeutics Inc
Veloxis Pharmaceuticals AS
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Lung Transplant Rejection reports